<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407094</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092010-151</org_study_id>
    <nct_id>NCT01407094</nct_id>
  </id_info>
  <brief_title>Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression</brief_title>
  <acronym>EMBARC</acronym>
  <official_title>Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine multiple carefully selected clinical and biological markers, using
      both existing state-of-the-art technologies as well as pioneering, innovative approaches. The
      study is designed to identify moderators and mediators of treatment response for depression
      in order to specify a biosignature of treatment response for depression. Evaluation of the
      usefulness of these markers in a carefully conducted clinical trial comparing an
      antidepressant to placebo will assist in developing a Depression Treatment Response Index
      (DTRI) to help clinicians match treatments to patients with MDD, resulting in timely
      selection of treatments best suited for individual patients and thus approaching personalized
      treatment. The resulting index provides a truly novel means of synthesizing the contribution
      of key clinical and biological parameters in an easy to use tool for clinical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed to identify biomarkers for the prediction of differential
      treatment outcomes between the SSRI antidepressant sertraline (SERT) and placebo (PBO) in a
      randomized trial for patients with MDD. In addition, a second stage will collect data to
      explore moderators and mediators of treatment outcomes between pharmacologically distinct
      active treatment arms: sertraline (SERT), a serotonergic antidepressant or bupropion (BUP), a
      nonserotonergic antidepressant. To reduce biologic heterogeneity, we will only enroll
      patients with early onset of DSM IV MDD (before age 30) because these criteria in probands
      have been shown to be associated with increased familial loading in families. Patients will
      also have recurrent MDD with 2 or more recurrences (including current episode). Additionally,
      patients will be required to have a current symptom severity score of 14 or more on the Quick
      Inventory of Depressive Symptomatology - Self Report (QIDS-SR), both at study screening and
      at the randomization (baseline) visit. In the first stage, patients will receive an 8−week
      course of treatment in one of the two study arms. As part of the Sequential Multiple
      Assignment Randomized Trial (SMART) design patients that have not achieved a response at the
      end of 8 weeks to their stage one treatment, defined by &lt; 50% improvement on the Clinical
      Global Improvement scale (CGI), will be switched to Stage 2 treatment (8 weeks). Patients who
      have achieved satisfactory response (&gt;= 50% improvement on the CGI) will be continued on
      treatment for an additional 8 weeks.

      Specific Aims

      Moderator Aims (Aim 1): To identify baseline clinical, neuroimaging, neurophysiological, and
      behavioral moderators of differential treatment outcome (mean symptom change and
      tolerability) for sertraline (SERT, a serotonergic antidepressant) versus placebo (PBO) for
      the treatment of MDD. Symptom change will be measured using the mean change from baseline in
      the 17-item Hamilton Rating Scale for Depression (HRSD17). Tolerability will be measured
      using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) and the Treatment
      Emergent Symptom Scale (TESS).

      Mediator Aims (Aim 2): To identify early phase (week 1) changes in neuroimaging,
      neurophysiological, and behavioral tasks as mediators of differential treatment outcomes
      (symptom change, tolerability) to SERT and PBO.

      Main Treatment Effects Aim (Aim 3): To compare the 8-week outcomes of SERT vs. PBO using
      mixed model regression analysis to maximize power to discriminate treatment efficacy
      differences.

      Primary Outcomes:

      - 17-item Hamilton Rating Scale for Depression (HRSD17)

      Secondary Outcomes:

      - the Frequency, Intensity, and Burden Side Effects Rating (FIBSER)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Patients were entered into Stage 1, treated with sertraline (Treatment A) or placebo (Treatment B), and used for the primary analysis which included the identification of potential mediators and moderators of response for these two treatments.
In stage two, responders to Treatment A remained on sertraline, and non-responders were switched to bupropion (Treatment C). Responders to Treatment B remained on placebo, and non-responders were switched to sertraline (Treatment D).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>Week 8</time_frame>
    <description>The Hamilton Rating Scale for depression is a measure of depressive severity (HAM-D17; HDRS)
Scores range from 0-52
Lower scores indicate less depressive symptomatology, and so are the more desirable.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SSRI monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BupropionXL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50-200mg/day</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-4 pills per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BupropionXL</intervention_name>
    <description>150-450 mg/day</description>
    <arm_group_label>Bupropion</arm_group_label>
    <other_name>WelbutrinXL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, age 18-65

          -  Written informed consent obtained

          -  Outpatients with a current primary diagnosis of nonpsychotic recurrent or chronic MDD
             per the SCID-I

          -  QIDS-SR score of ≥ 14 at Screening Visit and Randomization (Baseline) Visit

          -  No failed antidepressant trials of adequate dose and duration, as defined by the
             MGH-ATRQ, in the current episode

          -  Agrees to, and is eligible for, all biomarkers procedures (EEG/psychological testing,
             MRI, and blood draws)

        Exclusion Criteria:

          -  History of inadequate response (to trials at adequate dose for adequate duration) or
             poor tolerability to sertraline (SERT) or bupropion (BUP)

          -  Pregnant or breastfeeding

          -  Plan to become pregnant over the ensuing 12 months following study entry or are
             sexually active and not using adequate contraception

          -  History (lifetime) of psychotic depression, schizophrenia, bipolar (I, II, or NOS)
             disorder, schizoaffective disorder, or other Axis I psychotic disorder

          -  Current primary anxiety disorder diagnosis

          -  Meeting DSM-IV criteria for substance abuse in the last 2 months or substance
             dependence in the last 6 months (except for nicotine)

          -  Require immediate hospitalization for psychiatric disorder

          -  Have an unstable general medical condition (GMC) that will likely require
             hospitalization or to be deemed terminal (life expectancy &lt; 6 months after study
             entry)

          -  Require medications for their GMCs that contraindicate any study medication

          -  Have epilepsy or other conditions requiring an anticonvulsant

          -  Receiving or have received during the index episode vagus nerve stimulation, ECT, or
             rTMS, or other somatic antidepressant treatments

          -  Currently taking any of the following exclusionary medications: antipsychotic
             medications, anticonvulsant medications, mood stabilizers, central nervous system
             stimulants, daily use of benzodiazepines or hypnotics, or antidepressant medication
             used for the treatment of depression or other purposes such as smoking cessation,
             since these agents may interfere with the testing of the major hypotheses under study.
             Nonexcluded concomitant medications are acceptable as long as their clinician
             determines that antidepressant treatment is safe and appropriate.

          -  Significant liver disease that would contraindicate any study medication

          -  Taking thyroid medication for hypothyroidism may be included only if they have been
             stable on the thyroid medication for 3 months

          -  Using agents that are potential augmenting agents (e.g., T3 in the absence of thyroid
             disease, SAMe, St. John's Wort, lithium, buspirone, Omega 3 fatty acids)

          -  Therapy that is depression specific, such as CBT or Interpersonal Psychotherapy of
             Depression (IPT) is not allowed during participation (participants can participate if
             they are receiving psychotherapy that is not targeting the symptoms of depression,
             such as supportive therapy, marital therapy).

          -  Subjects must be fluent in English and have the capacity to understand the nature of
             the study and sign the written informed consent since non-English speaking personnel
             are not available for this study, and the research instruments are not yet translated
             and validated in other languages.

          -  Currently actively suicidal or considered a high suicide risk

          -  Are currently enrolled in another study, and participation in that study
             contraindicates participation in the EMBARC study.

          -  Any reason not listed herein yet, determined by the site PI, medical personnel, or
             designee that constitutes good clinical practice and that would in the opinion of the
             site PI, medical personnel, or designee make participation in the study hazardous.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhukar H Trivedi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick J McGrath, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myrna Weissman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramin Parsey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Fava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univerisity New York City</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://embarc.utsouthwestern.edu/</url>
    <description>EMBARC Study Website</description>
  </link>
  <reference>
    <citation>Chase HW, Fournier JC, Greenberg T, Almeida JR, Stiffler R, Zevallos CR, Aslam H, Cooper C, Deckersbach T, Weyandt S, Adams P, Toups M, Carmody T, Oquendo MA, Peltier S, Fava M, McGrath PJ, Weissman M, Parsey R, McInnis MG, Kurian B, Trivedi MH, Phillips ML. Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. PLoS One. 2015 May 11;10(5):e0126326. doi: 10.1371/journal.pone.0126326. eCollection 2015.</citation>
    <PMID>25961712</PMID>
  </reference>
  <reference>
    <citation>Fournier JC, Chase HW, Greenberg T, Etkin A, Almeida JR, Stiffler R, Deckersbach T, Weyandt S, Cooper C, Toups M, Carmody T, Kurian B, Peltier S, Adams P, McInnis MG, Oquendo MA, McGrath PJ, Fava M, Weissman M, Parsey R, Trivedi MH, Phillips ML. Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Mar;2(2):138-148. doi: 10.1016/j.bpsc.2016.11.008. Epub 2016 Dec 6.</citation>
    <PMID>28983519</PMID>
  </reference>
  <reference>
    <citation>Greenberg T, Chase HW, Almeida JR, Stiffler R, Zevallos CR, Aslam HA, Deckersbach T, Weyandt S, Cooper C, Toups M, Carmody T, Kurian B, Peltier S, Adams P, McInnis MG, Oquendo MA, McGrath PJ, Fava M, Weissman M, Parsey R, Trivedi MH, Phillips ML. Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. Am J Psychiatry. 2015 Sep 1;172(9):881-91. doi: 10.1176/appi.ajp.2015.14050594. Epub 2015 Jul 17.</citation>
    <PMID>26183698</PMID>
  </reference>
  <reference>
    <citation>Petkova E, Ogden RT, Tarpey T, Ciarleglio A, Jiang B, Su Z, Carmody T, Adams P, Kraemer HC, Grannemann BD, Oquendo MA, Parsey R, Weissman M, McGrath PJ, Fava M, Trivedi MH. Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study. Contemp Clin Trials Commun. 2017 Jun;6:22-30. doi: 10.1016/j.conctc.2017.02.007. Epub 2017 Feb 24.</citation>
    <PMID>28670629</PMID>
  </reference>
  <reference>
    <citation>Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello J, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Trivedi MH. Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Jun 1;75(6):547-554. doi: 10.1001/jamapsychiatry.2018.0252.</citation>
    <PMID>29641834</PMID>
  </reference>
  <reference>
    <citation>Trivedi MH, South C, Jha MK, Rush AJ, Cao J, Kurian B, Phillips M, Pizzagalli DA, Trombello JM, Oquendo MA, Cooper C, Dillon DG, Webb C, Grannemann BD, Bruder G, McGrath PJ, Parsey R, Weissman M, Fava M. A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychother Psychosom. 2018;87(5):285-295. doi: 10.1159/000491093. Epub 2018 Aug 15.</citation>
    <PMID>30110685</PMID>
  </reference>
  <reference>
    <citation>Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, Oquendo MA, Bruder G, Pizzagalli D, Toups M, Cooper C, Adams P, Weyandt S, Morris DW, Grannemann BD, Ogden RT, Buckner R, McInnis M, Kraemer HC, Petkova E, Carmody TJ, Weissman MM. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. J Psychiatr Res. 2016 Jul;78:11-23. doi: 10.1016/j.jpsychires.2016.03.001. Epub 2016 Mar 15.</citation>
    <PMID>27038550</PMID>
  </reference>
  <reference>
    <citation>Trombello JM, Pizzagalli DA, Weissman MM, Grannemann BD, Cooper CM, Greer TL, Malchow AL, Jha MK, Carmody TJ, Kurian BT, Webb CA, Dillon DG, McGrath PJ, Bruder G, Fava M, Parsey RV, McInnis MG, Adams P, Trivedi MH. Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. J Psychiatr Res. 2018 Jul;102:207-215. doi: 10.1016/j.jpsychires.2018.04.003. Epub 2018 Apr 6.</citation>
    <PMID>29689518</PMID>
  </reference>
  <reference>
    <citation>Ulke C, Tenke CE, Kayser J, Sander C, Böttger D, Wong LYX, Alvarenga JE, Fava M, McGrath PJ, Deldin PJ, Mcinnis MG, Trivedi MH, Weissman MM, Pizzagalli DA, Hegerl U, Bruder GE. Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. Clin EEG Neurosci. 2019 Jan;50(1):3-12. doi: 10.1177/1550059418795578. Epub 2018 Sep 5.</citation>
    <PMID>30182751</PMID>
  </reference>
  <reference>
    <citation>Webb CA, Trivedi MH, Cohen ZD, Dillon DG, Fournier JC, Goer F, Fava M, McGrath PJ, Weissman M, Parsey R, Adams P, Trombello JM, Cooper C, Deldin P, Oquendo MA, McInnis MG, Huys Q, Bruder G, Kurian BT, Jha M, DeRubeis RJ, Pizzagalli DA. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychol Med. 2019 May;49(7):1118-1127. doi: 10.1017/S0033291718001708. Epub 2018 Jul 2.</citation>
    <PMID>29962359</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <results_first_submitted>July 19, 2018</results_first_submitted>
  <results_first_submitted_qc>December 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2018</results_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Madhukar H. Trivedi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Depression, Major Depressive Disorder, Mood Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Final enrollment Stage 1: 296 (146 SERT, 150 PBO). Individuals who responded to their Stage 1 treatment remained on that treatment in Stage 2. Individuals who did not respond to their Stage 1 treatment were switched to a different treatment in Stage 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertraline</title>
          <description>SSRI monotherapy
Sertraline: 50-200mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo control
Placebo: 1-4 pills per day</description>
        </group>
        <group group_id="P3">
          <title>BupropionXL</title>
          <description>BupropionXL
150-450 mg/day
Other names: WelbutrinXL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146">Stage 1 Sertraline (SERT): 34 exited</participants>
                <participants group_id="P2" count="150">Stage 1 Placebo (PBO): 27 exited.</participants>
                <participants group_id="P3" count="0">Bupropion (BUP) was used only in Stage 2 for non-responders to SERT.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112">One participant completed Stage 1 but did not continue to Stage 2.</participants>
                <participants group_id="P2" count="123">Four participants completed Stage 1 but did not continue to Stage 2.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134">Stage 2 SERT includes Stage 1 SERT responders (n=61) and Stage 1 PBO non-responders (n=73).</participants>
                <participants group_id="P2" count="46">Stage 2 PBO includes Stage 1 PBO responders (n=47); 1 early exit (n=46).</participants>
                <participants group_id="P3" count="53">Stage 2 BUP includes Stage 1 SERT non-responders (n=54); 1 early exit (n=53).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stage 1 is made up of Treatment A (SERT) and Treatment B (PBO). Non-responders to Treatment A were switched in Stage 2 to BUP, and non-responders in Treatment B were switched to SERT. Between randomization and baseline, 3 participants didn't meet inclusion criteria, hence the discrepancy between official enrollment and baseline population numbers.</population>
      <group_list>
        <group group_id="B1">
          <title>Sertraline</title>
          <description>SSRI monotherapy
Sertraline: 50-200mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo control
Placebo: 1-4 pills per day</description>
        </group>
        <group group_id="B3">
          <title>BupropionXL</title>
          <description>BupropionXL
150-450mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="146"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Of the 299 participants who were randomized, 3 were randomized but did not meet criteria, resulting in 296 who were randomized and assessed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B4" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="13.8"/>
                    <measurement group_id="B2" value="36.9" spread="12.8"/>
                    <measurement group_id="B4" value="37.05" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Measure Analysis Population Description: Of the 299 participants who were randomized, 3 were randomized but did not meet criteria, resulting in 296 who were randomized and assessed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B4" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression</title>
        <description>The Hamilton Rating Scale for depression is a measure of depressive severity (HAM-D17; HDRS)
Scores range from 0-52
Lower scores indicate less depressive symptomatology, and so are the more desirable.</description>
        <time_frame>Week 8</time_frame>
        <population>Note subjects in the efficacy trial were those that completed 8 weeks of treatment, 115 in the sertraline group, and 123 in the placebo group. SERT had 34 wash-outs, PBO had 27.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>SSRI monotherapy
Sertraline: 50-200mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo control
Placebo: 1-4 pills per day</description>
          </group>
          <group group_id="O3">
            <title>BupropionXL</title>
            <description>BupropionXL
150-450mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression</title>
          <description>The Hamilton Rating Scale for depression is a measure of depressive severity (HAM-D17; HDRS)
Scores range from 0-52
Lower scores indicate less depressive symptomatology, and so are the more desirable.</description>
          <population>Note subjects in the efficacy trial were those that completed 8 weeks of treatment, 115 in the sertraline group, and 123 in the placebo group. SERT had 34 wash-outs, PBO had 27.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.06" spread="6.71"/>
                    <measurement group_id="O2" value="12.52" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks for each Stage (1 and 2)</time_frame>
      <desc>For both Serious and Other adverse events: SERT total is the sum of Stages 1 or 2, Treatment A plus Treatment D (210+73); PBO total is the sum of Stages 1 or 2, Treatment B (150+46). BUP was only used during Stage 2 (Treatment C).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertraline</title>
          <description>SSRI monotherapy
Sertraline: 50-200mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo control
Placebo: 1-4 pills per day</description>
        </group>
        <group group_id="E3">
          <title>BupropionXL</title>
          <description>BupropionXL
150-450 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>Chest pain with emergency hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>Type-I Diabetes with brittle blood sugar control; hospital admin w/ ketoacidosis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>ER visit with diagnosis of acute cholecystitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>ER visit with fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>Chest pain with emergency hospitalization; diagnosis of non-cardiac chest pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidality</sub_title>
                <description>Emergent suicidality</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Suicidality</sub_title>
                <description>Involuntary hospitalization for suicidality</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Suicidality</sub_title>
                <description>Worsening depression, suicidal ideation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>Panic attack, arrested</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>Panic attack</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>ER Visit</sub_title>
                <description>Worsening depression, suicidal ideation to ER</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Suicidality</sub_title>
                <description>Hospitalization for suicidality</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Worsening depression, suicidal ideation; psych hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>Became pregnant</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>Exited study due to pregnancy on 9/16/12 and gave birth to microcephalic child on 5/7/13</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="283"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="283"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="283"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="283"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="283"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="283"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="196"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="283"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="283"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Madhukar H. Trivedi</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-0188</phone>
      <email>madhukar.trivedi@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

